Acadia rises as EU backs Rett syndrome therapy
Seeking Alpha ·
Acadia Pharmaceuticals ( ACAD ) added ~13% on Friday after an expert panel of the EU drug regulator, the European Medicines Agency, endorsed granting marketing authorization for Daybu, a treatment for a rare genetic neurodevelopmental disorder called Rett syndrome.
DYAX Investor Sentiment
Bullish (Long) 55% · Bearish (Short) 45%
509 participants
Related News
- Stock market stays ‘very solid’ thanks to strong earnings amid ‘AI fatigue’ – Ed Yardeni
- Is SpaceX Overvalued Right Now?
- Wall Street Has 36 Buy Ratings on Oracle. Here’s How We See 47% Upside
- $30 Billion in Stocks Are About to Hit the Market in 2 Days, and One Strategist Says: Buy It
- Umicore - Transparency notification by JP Morgan Chase & Co.
- Analyst Behind $250 SpaceX Target Says Physical AI Will Be “One of AI’s Fastest-Growing Areas Over the Next 4-5 Years”